Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-08 in 18d
ESTIMATED |
READOUT
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participant
Phase 2 · Renal Cell Carcinoma |
Hoffmann-La Roche | Tobemstomig, Tiragolumab, Pembrolizumab, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|